"A 'Beta-cell centric' Triple Combination of Metformin, an Angiotensin II Receptor Type I Blocker (ARB) and a selective Cyclooxygenase-2 Inhibitor show promise of providing Long-Term Glycemic Control for Type 2 Diabetes Patients"
The proposed doses of selective Cyclooxygenase-2 (Cox-2) inhibitor, Celecoxib are safe for chronic use in patients with cardiovascular disease risk.
“As the founder and innovator, before I could ask others to invest in my company, I wanted to make sure that I take the risk with my money and establish the proof-of-concept, which we have accomplished already”
Dr. Ravi Kumar
October 3, 2016 Issue
Read Full Article
A New Shift in the Paradigm
"Signaling pathways associated with immune dysregulation, obesity-triggered chronic low-grade inflammation, insulin resistance and cardiovascular disease are intricately intertwined and they are inseparable from each other. For efficient clinical management of insulin resistance, chronic hyperglycemia due to glucose intolerance should not be treated in isolation without treating the causative inflammation. Lowering inflammatory parameters, treating pancreatic beta cell dysfunction, managing hypertension and lowering lipid levels are expected to result in a more rapid improvement in clinical outcomes with optimal glycemic control."
Ravi Kumar, Ph.D.
Founder & CEO
Immune Dysregulation-Inflammation-Insulin Resistance Axis
“I agree that you have an interesting angle and great leadership/SAB advice. There is definitely a lot of unmet medical need in this area and I think that targeting inflammation has a lot of potential. I hope your efforts are highly successful!”
Christopher K. Glass, M.D., Ph.D.
Professor of Cellular & Molecular Medicine
Professor of Medicine
Ben & Wanda Hildyard
Chair in Hereditary Diseases School of Medicine
University of California, San Diego